The genetics of neurodegenerative diseases

Journal of Neurochemistry

Volumn 97, Issue 6, 2006, Pages 1690-1699

  Hardy, John ^a,b   Orr, Harry ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

synuclein; Ataxia; Dementia; Parkinsonism; Polyglutamine; Tau

Indexed keywords

ATAXIN 1; ATAXIN 3; POLYGLUTAMINE; SYNUCLEIN; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL INCLUSION; CHROMOSOME 17; CHROMOSOME 9P; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DISEASE COURSE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PAGET BONE DISEASE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RISK FACTOR; SPINOCEREBELLAR DEGENERATION; SUBACUTE SCLEROSING PANENCEPHALITIS; TAUOPATHY; THOMSEN DISEASE;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PEPTIDES; TAU PROTEINS;

ANIMALIA;

EID: 33745018376     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.03979.x     Document Type: Review

References (74)

1. Abou-Sleiman P. M. Muqit M. M. Wood N. W. 2006 Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207 219.
2. Arrasate M. Mitra S. Schweitzer E. S. Segal M. R. Finkbeiner S. 2004 Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805 810.
3. Bancher C. Leitner H. Jellinger K. Eder H. Setinek U. Fischer P. Wegiel J. Wisniewski H. M. 1996 On the relationship between measles virus and Alzheimer neurofibrillary tangles in subacute sclerosing panencephalitis. Neurobiol. Agingaug. 17, 527 533.
4. Browne S. E. Beal M. F. 2004 The energetics of Huntington's disease. Neurochem. Res. 29, 531 546.
5. Burnett B. Li F. Pittman R. N. 2003 The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitinylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12, 3195 3205.
6. Chai Y. Berke S. S. Cohen R. E. Paulson H. L. 2004 Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J. Biol. Chem. 279, 3605 3611.
7. Cookson M. R. Xiromerisiou G. Singleton A. 2005 December How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr. Opin. Neurol. 18, 706 711.
8. Cox P. A. Sacks O. W. 2002 Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 58, 956 959.
9. Dickman M. S. 2001 von Economo encephalitis. Arch. Neurol. 58, 1696 1698.
10. Emamian E. S. Kaytor M. D. Duvick L. A. Zu T. Susan K. Tousey S. K. Zoghbi H. Y. Clark H. B. Orr H. T. 2003 Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375 387.
11. Evans W. et al. 2004 The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci. Lett. 369, 183 185.
12. Ferrer I. Goutan E. Marin C. Rey M. J. Ribalta T. 2000 Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866, 257 261.
13. Foster N. L. Wilhelmsen K. Sima A. A. Jones M. Z. D'Amato C. J. Gilman S. 1997 Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann. Neurol. 41, 706 715.
14. Gatchel J. R. Zoghbi H. Y. 2005 Diseases of unstable repeat expansion: mechanism and common principles. Nat. Rev. Genet. 6, 743 755.
15. Gauthier L. R. Charrin B. C. Borrell-pages M. et al. 2004 Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127 138.
16. Gilks W. P. Abou-Sleiman P. M. Gandhi S. et al. 2005 A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415 416.
17. Glabe C. G. 2006 Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570 575.
18. Golde T. E. 2005 The Abeta hypothesis. leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 15, 84 87.
19. Gunawardena S. Goldstein L. S. 2005 Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch. Neurol. 62, 46 51.
20. Hardy J. Lees A. J. 2005 Parkinson's disease: a broken nosology. Mov. Disord. 20, S2 S4.
21. Hardy J. Selkoe D. J. 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353 356.
22. Hardy J. Duff K. Gwinn-Hardy K. Pérez-Tur J. Hutton M. 1998 Genetic dissection of Alzheimer's disease and related dementias. amyloid and its relationship to tau. Nat. Neurosci. 1, 355 358.
23. Hardy J. Momeni P. Traynor B. J. 2006 Frontal temporal dementia: dissecting the aetiology and pathogenesis. Brain 129, 830 831.
24. Hashimoto M. Rockenstein E. Masliah E. 2003 Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. NY Acad. Sci. 991, 171 188.
25. Hughes A. J. Daniel S. E. Lees A. J. 2001 Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57, 1497 1499.
26. Hutton M. 2001 Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56, S21 S25.
27. Hutton M. Lewis J. Dickson D. Yen S. H. McGowan E. 2001 Analysis of tauopathies with transgenic mice. Trends Mol. Med. 7, 467 470.
28. Ingram E. M. Spillantini M. G. 2002 Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol. Med. 8, 555 562.
29. Katsuno M. Adachi H. Kume A. Li M. Nakagomi Y. Niwa H. Sang C. Kobayashi Y. Doyu M. Sobue G. 2002 Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843 854.
30. Katsuno M. Adachi H. Doyu M. Minamiyama M. Sang C. Kobayashi Y. Inukai A. Sobue G. 2003 Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9, 768 773.
31. Klein W. L. Stine W. B. Jr. Teplow D. B. 2004 Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging. 25, 569 580.
32. Klement I. A. Skinner P. J. Kaytor M. D. Yi H. Hersch S. M. Clark H. B. Zoghbi H. Y. Orr H. T. 1998 Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41 53.
33. Kurland L. T. Hirano A. Malaud N. Lessell S. 1961 Parkinsonism-dementia complex, en endemic disease on the island of Guam. Clinical, pathological, genetic and epidemiological features. Trans. Am. Neurol. Assoc. 86, 115 120.
34. La Spada A. R. Wilson E. M. Lubahn D. B. Harding A. E. Fischbeck K. H. 1991 Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77 79.
35. LaFerla F. M. Oddo S. 2005 April Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 11, 170 176.
36. Lee H. G. Castellani R. J. Zhu X. Perry G. Smith M. A. 2005 June Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int. J. Exp. Pathol. 86, 133 138.
37. Lee V. M. Goedert M. Trojanowski J. Q. 2001 Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121 1159.
38. Lee V. M. Giasson B. I. Trojanowski J. Q. 2004 More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 27, 129 134.
39. Leigh P. N. Whitwell H. Garofalo O. Buller J. Swash M. Martin J. E. Gallo J. M. Weller R. O. Anderton B. H. 1991 Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morph. Dist. Spec. Brain 114, 775 788.
40. Lesne S. Koh M. T. Kotilinek L. Kayed R. Glabe C. G. Yang A. Gallagher M. Ashe K. H. 2006 A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352 357.
41. Mackenzie I. R. Feldman H. H. 2005 Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J. Neuropathol. Exp. Neurol. 64, 730 739.
42. Mackenzie I. R. Baker M. West G. et al. 2006 A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain 129, 853 867.
43. Mangiarini L. et al. 1996 Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87, 493 506.
44. Masliah E. Rockenstein E. Adame A. et al. 2005 Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857 868.
45. Morita M. Al-Chalabi A. Andersen P. M. et al. 2006 A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 28, 839 844.
46. Morris H. R. Steele J. C. Crook R. et al. 2004 Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch. Neurol. 61, 1889 1897.
47. Mulder D. W. Kurland L. T. Iriarte L. L. 1954 Neurologic diseases on the island of Guam. US Armed Forces Med. J. 5, 1724 1739.
48. Noble W. Planel E. Zehr C. et al. 2005 May 10 Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990 6995.
49. Poorkaj P. Tsuang D. Wijsman E. et al. 2001 TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. Arch. Neurol. 58, 1871 1878.
50. Rapoport M. Dawson H. N. Binder L. I. Vitek M. P. Ferreira A. 2002 Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99, 6364 6369.
51. Rogaeva E. 2002 The solved and unsolved mysteries of the genetics of early-onset alzheimer's disease. Neuromolecular Med. 2, 1 10.
52. Rovelet-Lecrux A. Hannequin D. Raux G. et al. 2006 APP locus duplication causes autosomal dominant early-onset alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24 26.
53. Schenk D. Hagen M. Seubert P. 2004 Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16, 599 606.
54. Schmidt B. J. Greenberg C. R. Allingham-Hawkins D. J. Sproggsm E. L. 2002 Expression of X-linked bulbospin al muscular atrophy (kennedy's disease) in two homozygous women. Neurology 59, 770 772.
55. Schroder R. Watts G. D. J. Mehta S. G. Evert B. O. Broich P. Fliessbach K. Pauls K. Hans V. H. Kimonis V. Thal D. R. 2005 Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann. Neurol. 57, 457 461.
56. Seong I. S. Ivanova E. Lee J.-M. et al. 2005 HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871 2880.
57. Sergeant N. Delacourte A. Buee L. 2005 Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta 1739, 179 197.
58. Singleton A. B. 2005 Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurosci. 28, 416 421.
59. Singleton A. Myers A. Hardy J. 2004 The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum. Mol. Genet. 13 Spec. 1, R123 R126.
60. Spillantini M. G. Schmidt M. L. Lee V. M. Trojanowski J. Q. Jakes R. Goedert M. 1997 August 28 Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
61. Stefansson H. et al. 2005 A common inversion under selection in Europeans. Nat. Genet. 37, 129 137.
62. Sugars K. L. Rubinsztein D. C. 2003 Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233 238.
63. Takeyama K. Ito S. Yamaoto A. Tanimoto H. Furutani T. Kanuka H. Miura M. Tabata T. Kato S. 2002 Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855 864.
64. Tarlac V. Storey E. 2003 Role of proteolysis in polyglutamine disorders. J. Neurosci. Res. 74, 406 416.
65. van der Zee J. et al. 2006 A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain 129, 841 852.
66. Vance C. et al. 2006 Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129, 868 876.
67. Waring S. C. Esteban-Santillan C. Reed D. M. Craig U. K. Labarthe D. R. Petersen R. C. Kurland L. T. 2004 Incidence of amyotrophic lateral sclerosis and of the parkinsonism-dementia complex of Guam, 1950-89. Neuroepidemiologyaug 23, 192 200.
68. Warrick J. M. Morabito L. M. Bilen J. Gordesky-Gold B. Faust L. Z. Paulson H. L. Nancy M. Bonini N. M. 2005 Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell 18, 37 48.
69. Watts G. D. J. Wymer J. Kovach M. J. Mehta S. G. Mumm S. Darvish D. Pestronk A. Whyte M. P. Kimonis V. E. 2004 Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377 381.
70. West A. B. Moore D. J. Biskup S. Bugayenko A. Smith W. W. Ross C. A. Dawson V. L. Dawson T. M. 2005 Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16 842 16 847.
71. Wilquet V. De Strooper B. 2004 Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 14, 582 588.
72. Zimprich A. Biskup S. Leitner P. et al. 2004 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601 607.
73. Zoghbi H. Y. Orr H. T. 2000 Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217 247.
74. Zuccato C. Ciammola A. Rigamonti D. et al. 2001 Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493 498.